Improved survival for patients with de novo metastatic prostate cancer in the last 20 years.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsBerg, Kasper Drimer
Thomsen, Frederik Birkebæk
Mikkelsen, Marta K
Ingimarsdóttir, Inga J
Hansen, Rikke B
Kejs, Anne Mette T
MetadataShow full item record
CitationImproved survival for patients with de novo metastatic prostate cancer in the last 20 years. 2017, 72:20-27 Eur. J. Cancer
AbstractDuring recent years, several new life-prolonging therapeutic options have been introduced for patients with metastatic prostate cancer (mPCa). The aim of the present study was to evaluate the changes in the survival of patients diagnosed with mPCa prior to and in the early period of the implementation of these new agents.
The study population consisted of 207 men diagnosed in 1997 and 316 men diagnosed in the period 2007-2013 with de novo mPCa and managed with initial endocrine therapy. Men were followed for overall survival and PCa-specific survival.
At the time of diagnosis, men diagnosed in the period 2007-2013 had less co-morbidity, lower prostrate-specific antigen levels and lower clinical tumour categories than men diagnosed in 1997. A significantly higher proportion of men diagnosed in 1997 were managed with surgical castration (57% versus 9%). Only one patient diagnosed in 1997 received second-line therapy compared with 81 men (26%) diagnosed in the period 2007-2013. The median overall survival was significantly longer for men diagnosed between 2007 and 2013 compared with men diagnosed in 1997 (39.4 months versus 24.2 months, p < 0.0001). Likewise, the cumulative incidence of PCa-specific death was higher among men diagnosed in 1997 compared with men diagnosed between 2007 and 2013, with 5-year cumulative incidences of 72% and 47%, respectively (p < 0.0001).
Survival in men diagnosed with metastatic PCa has improved significantly over time. The improved survival can in part be explained by lead-time bias, but also by the introduction of new life-prolonging treatments.
DescriptionNeðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/Open To access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to European journal of cancer (Oxford, England : 1990)
- Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
- Authors: Culp SH, Schellhammer PF, Williams MB
- Issue date: 2014 Jun
- Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.
- Authors: Bandini M, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, Briganti A, Saad F, Karakiewicz PI
- Issue date: 2018 Jan
- Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
- Authors: Helgstrand JT, Røder MA, Klemann N, Toft BG, Lichtensztajn DY, Brooks JD, Brasso K, Vainer B, Iversen P
- Issue date: 2018 Jul 15
- No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period.
- Authors: Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA
- Issue date: 2014 Mar 15
- The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
- Authors: Kim KH, Han KS, Kim KH, Kim DK, Koo KC, Rha KH, Choi YD, Hong SJ
- Issue date: 2015 Sep